Novartis' Gleevec indicates potential to treat Alzheimer's

09/1/2010 | Reuters

U.S. researchers found that Novartis' cancer drug Gleevec has the ability to block the beta-amyloid protein that triggers development of brain-damaging plaques in mice with Alzheimer's disease. "The development of compounds that work like Gleevec, but have the ability to pass the blood-brain barrier and target gamma-secretase activating protein could revolutionize the treatment of this disease," the lead researcher said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ